FindTrial
Sign In

denileukin diftitox

BIOLOGICAL20 trials

Sponsors

Eastern Cooperative Oncology Group, Ligand Pharmaceuticals, Pharmatech Oncology, National Cancer Institute (NCI), Wake Forest University Health Sciences

Conditions

Anaplastic Large-Cell LymphomaBreast CancerColorectal CancerDrug/Agent Toxicity by Tissue/OrganFallopian Tube CancerGraft vs Host DiseaseHER2-positive Breast CancerImmune System Disorders

Early Phase 1

Pilot Study of Denileukin Diftitox Plus High-Dose IL-2 for Patients With Metastatic Renal Cancer
CompletedNCT00278369
Northwestern UniversityKidney Cancer
Start: 2005-04-30End: 2010-09-30Updated: 2013-05-22

Phase 1

Denileukin Diftitox Followed by Vaccine Therapy in Treating Patients With Metastatic Cancer
CompletedNCT00128622
H. Kim LyerlyBreast Cancer, Colorectal Cancer, Lung Cancer +2
Start: 2005-09-30End: 2009-05-31Updated: 2012-11-12
Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine
CompletedNCT00228358
University of WashingtonHER2-positive Breast Cancer, Recurrent Breast Cancer, Recurrent Non-small Cell Lung Cancer +6
Start: 2003-06-30Updated: 2014-11-11
Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer
CompletedNCT00357448
University of WashingtonFallopian Tube Cancer, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma +8
Start: 2005-04-30Updated: 2019-05-14
Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma
TerminatedNCT00945269
Fred Hutchinson Cancer CenterRecurrent Melanoma, Stage III Melanoma, Stage IV Melanoma
Start: 2009-07-31End: 2011-01-31Updated: 2022-11-15

Phase 2

Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma
CompletedNCT00003615
Eastern Cooperative Oncology GroupLymphoma
Start: 1999-05-20Target: 77Updated: 2023-06-15
Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma
NCT00026429
Pharmatech OncologyLeukemia, Lymphoma
Start: 2001-01-31Updated: 2013-12-18
Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell Lymphoma
CompletedNCT00006345
Ligand PharmaceuticalsDrug/Agent Toxicity by Tissue/Organ, Lymphoma
Start: 1999-11-30End: 2004-03-31Updated: 2013-05-30
Denileukin Diftitox in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer
CompletedNCT00082914
National Cancer Institute (NCI)Kidney Cancer, Melanoma (Skin)
Start: 2004-03-31End: 2006-07-31Updated: 2013-06-20
Denileukin Diftitox in Treating Patients With Fludarabine-Refractory B-Cell Chronic Lymphocytic Leukemia
CompletedNCT00082940
Wake Forest University Health SciencesLeukemia
Start: 2002-08-31End: 2005-06-30Updated: 2017-01-19
Denileukin Diftitox in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
CompletedNCT00138164
Jonsson Comprehensive Cancer CenterLymphoma
Start: 2004-12-31End: 2008-11-30Target: 50Updated: 2013-05-30
A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma
CompletedNCT00211185
Eisai Inc.Lymphoma, T-Cell, Peripheral
Start: 2004-03-14End: 2009-12-23Updated: 2020-03-18
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
CompletedNCT00224874
National Heart, Lung, and Blood Institute (NHLBI)Graft vs Host Disease, Immune System Disorders
Start: 2005-09-30End: 2012-06-30Updated: 2021-11-01
Phase II Trial of Ontak With Metastatic Melanoma
CompletedNCT00299689
James Graham Brown Cancer CenterMalignant Melanoma
Start: 2006-03-31End: 2010-01-31Updated: 2014-09-05
Rituximab and Denileukin Diftitox in Treating Patients With Previously Untreated Stage III or Stage IV Follicular B-Cell Non-Hodgkin's Lymphoma
CompletedNCT00460109
Alliance for Clinical Trials in OncologyLymphoma
Start: 2008-04-30End: 2011-03-31Updated: 2017-04-18
Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)
TerminatedNCT00632827
University of California, San FranciscoPeripheral T-Cell Lymphoma
Start: 2008-07-01End: 2016-06-23Updated: 2020-04-27
Denileukine Diftitox for Relapsed ALCL
WithdrawnNCT00801918
Columbia UniversityAnaplastic Large-Cell Lymphoma
Start: 2008-12-31End: 2012-06-30Updated: 2013-05-15
Haploidentical Natural Killer Cells to Treat Refractory or Relapsed Acute Myelogenous Leukemia (AML)
TerminatedNCT01106950
Masonic Cancer Center, University of MinnesotaLeukemia, Myelogenous, Acute
Start: 2010-07-31End: 2012-12-31Updated: 2017-12-28
Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma
CompletedNCT01127451
Eisai Inc.Stage IIIC Melanoma, Stage IV Melanoma
Start: 2010-06-22End: 2015-04-07Updated: 2022-04-13

Unknown Phase

Combination Chemotherapy and Denileukin Diftitox in Treating Patients With Newly Diagnosed T-Cell Non-Hodgkin Lymphoma
WithdrawnNCT00513188
University of MiamiLymphoma
Start: 2007-02-28Updated: 2016-12-15

Related Papers

Intraperitoneal immunotherapy with denileukin diftitox (ONTAK) in recurrent refractory ovarian cancer.
2024-10-021 citations
Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein
Blood2014-04-10423 citations
Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study.
2012-03-01133 citations
Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma.
2011-12-1345 citations
Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network.
2009-05-14152 citations
Transient T cell depletion causes regression of melanoma metastases.
2008-03-11107 citations